NRX Pharmaceuticals Inc./$NRXP
1D1W1MYTD1Y5YMAX
Capital at risk
About NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
- Ticker
- $NRXP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 29
- Headquarters
- Wilmington, United States
- Website
- www.nrxpharma.com
NRXP Metrics
BasicAdvanced
$147M
-
-$0.78
2.18
-
Price and volume
Market cap
$147M
Beta
2.18
52-week high
$5.06
52-week low
$1.62
Average daily volume
979K
Financial strength
Current ratio
0.861
Quick ratio
0.794
Long term debt to equity
-2.682
Total debt to equity
-4.906
Interest coverage (TTM)
-17.50%
Profitability
EBITDA (TTM)
-19.762
Gross margin (TTM)
46.64%
Net profit margin (TTM)
-691.81%
Operating margin (TTM)
-588.21%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-63.99%
Return on equity (TTM)
131.23%
Valuation
Price to revenue (TTM)
30.334
Price to book
-862.51
Price to tangible book (TTM)
-52.46
Price to free cash flow (TTM)
-4.981
Free cash flow yield (TTM)
-20.08%
Free cash flow per share (TTM)
-0.683
Growth
Earnings per share change (TTM)
-66.98%
3-year earnings per share growth (CAGR)
-48.53%
Upcoming events
No upcoming events
NRXP News
AllArticlesVideos

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
MarketBeat1 month ago

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.